insiderdelta
CoverageForm 410-K10-Q8-K13D13G13F

MIRA · Mira Pharmaceuticals, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · MIRA

1YMax
Sign in to download
AnnualQuarterly

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D$524.8K-$412.6K$496.2K$314.4K-$1.07M($101.0K)$762.3K-
SG&A$578.7K-$904.3K$1.05M$1.49M-$1.01M$1.12M$1.01M-
Total Operating Expenses$1.10M-$1.32M$1.55M$1.81M-$2.08M$1.73M$1.77M-
D&A----------
Operating Income----------
Interest Expense----($21.4K)-($37.8K)($39.4K)($50.4K)-
Income Tax----------
Net Income($1.15M)-($1.14M)($1.54M)($1.78M)-($2.04M)($1.69M)($1.72M)-
EPS - Basic($0.03)-($1.18)($0.09)($0.11)-($0.14)($0.11)($0.12)-
EPS - Diluted($0.03)-($1.18)($0.09)($0.11)-($0.14)($0.11)($0.12)-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$4.82M$6.35M$2.64M$730.5K$2.83M$2.83M$4.14M$2.82M$3.53M$4.60M
Accounts Receivable----------
Inventory----------
Accounts Payable$34.0K$129.2K$83.9K$298.5K$423.3K---$636.3K$538.6K
Current Assets$9.43M$11.06M$7.60M$832.9K$1.36M$2.89M$4.23M$2.93M$3.71M$4.86M
Total Assets$9.46M$11.09M$7.63M$868.3K$1.40M$2.92M$4.27M$3.02M$3.81M$4.93M
Current Liabilities$114.8K$702.1K$83.9K$298.5K$106.2K$723.3K$692.8K$796.6K$652.0K$558.1K
Long-term Debt----------
Total Liabilities$114.8K$702.1K$83.9K$298.5K$106.2K$723.3K$692.8K$796.6K$652.0K$558.1K
Stockholders' Equity$9.35M$10.39M$7.55M$569.9K$1.29M$2.20M$3.57M$2.22M$3.16M$4.37M
Retained Earnings($40.73M)($39.58M)($33.60M)($32.46M)($30.92M)($29.14M)($26.74M)($24.69M)($23.00M)($21.29M)

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow($1.20M)---($1.63M)---($1.05M)-
Investing Cash Flow----------
Financing Cash Flow($330.6K)---$3.4K---($24.3K)-
CapEx----------
Free Cash Flow----------

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate----------
Return on assets-12.2%--14.9%-177.1%-127.4%--47.9%-56.1%-45.1%-
Return on equity-12.3%--15.1%-269.8%-137.8%--57.2%-76.2%-54.4%-
Return on invested capital----------
Liquidity
Current ratio82.1615.7590.532.7912.863.996.113.685.708.70
Quick ratio82.1615.7590.532.7912.863.996.113.685.708.70
Cash ratio41.969.0431.472.4526.683.925.983.545.418.25
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage----------
Equity multiplier1.011.071.011.521.081.331.191.361.211.13
Liabilities / Assets0.010.060.010.340.080.250.160.260.170.11
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B--3.5x36.1x12.6x-5.5x4.2x6.9x-
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)----------
Net income growth (YoY)35.5%-44.3%9.1%-3.8%--12.9%30.2%--
EPS growth (YoY)72.7%--742.9%18.2%8.3%-46.2%-10.0%--
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)622.4%372.4%111.2%-74.3%-59.0%-49.7%-56.0%---

Peer comparison

Same SIC group: Pharmaceutical Preparations

CompanyRevenue (last FY)Net marginROE
LLY$65.18B31.7%77.8%
UTHR$3.18B41.9%18.8%
PFE$62.58B12.4%9.0%
ZTS$9.47B28.2%80.2%
VRTX$12.00B32.9%21.2%

Comparing MIRA PHARMACEUTICALS against the 5 most active filers in the same SIC group.